INM176
PreclinicalSmall molecule
INM176 is one of 32 small molecule programs targeting Prostate Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Xaluritamig
AmgenPhase 3
Radium-223
BayerPhase 3
Triptorelin Embonate
IpsenPhase 3
Lhrha
Johnson & JohnsonPhase 3
Docetaxel /m²
AstraZenecaPhase 3
Luteinizing Hormone Releasing Hormone
UUS Department of Veterans Affairs
Phase 3
Fuzuloparib
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for INM176. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMilton S. Hershey Medical Center